Cancer Type: Lung

For more information about any of the clinical trials listed on this site, call 314-747-7222 or 800-600-3606 toll free or email Patient_Care_[email protected].

Select Basic Search to view clinical trials grouped by category and Advanced Search to be able to further narrow search results.

 

201902012

Brief Summary This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab with SoC SBRT versus placebo with SoC SBRT in patients with unresected clinical Stage I/II lymph node-negative (T1 to T3N0M0) NSCLC.

201906081

Brief Summary Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.